EP0594595A1 - Neue 4-methyl-thiazol-derivate, verfahren zur herstellung und diese verbindungen enthaltende arzneimittel - Google Patents
Neue 4-methyl-thiazol-derivate, verfahren zur herstellung und diese verbindungen enthaltende arzneimittelInfo
- Publication number
- EP0594595A1 EP0594595A1 EP91904815A EP91904815A EP0594595A1 EP 0594595 A1 EP0594595 A1 EP 0594595A1 EP 91904815 A EP91904815 A EP 91904815A EP 91904815 A EP91904815 A EP 91904815A EP 0594595 A1 EP0594595 A1 EP 0594595A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- methyl
- piperazinyl
- thiazole
- thiazolyloxy
- propanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4-methylthiazole Chemical class CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 title claims description 5
- 238000000034 method Methods 0.000 claims abstract description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 7
- 208000013403 hyperactivity Diseases 0.000 claims abstract description 7
- 210000002820 sympathetic nervous system Anatomy 0.000 claims abstract description 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract 2
- 150000002367 halogens Chemical class 0.000 claims abstract 2
- -1 4-phenyl-1-piperazinyl Chemical group 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 32
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 26
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 21
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 12
- IIMLZWMRQNCPTM-UHFFFAOYSA-N 5-bromo-4-methyl-1,3-thiazole Chemical compound CC=1N=CSC=1Br IIMLZWMRQNCPTM-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 239000001294 propane Substances 0.000 claims description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 2
- 230000031709 bromination Effects 0.000 claims description 2
- 238000005893 bromination reaction Methods 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 230000009615 deamination Effects 0.000 claims description 2
- 238000006481 deamination reaction Methods 0.000 claims description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000000047 product Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000012429 reaction media Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229960002748 norepinephrine Drugs 0.000 description 6
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
- UPUWMQZUXFAUCJ-UHFFFAOYSA-N 2,5-dihydro-1,2-thiazole Chemical compound C1SNC=C1 UPUWMQZUXFAUCJ-UHFFFAOYSA-N 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XZYIDZIGJVUTKE-UHFFFAOYSA-N 5-bromo-4-methyl-1,3-thiazol-2-amine Chemical compound CC=1N=C(N)SC=1Br XZYIDZIGJVUTKE-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 231100000111 LD50 Toxicity 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 2
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004508 fractional distillation Methods 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960001783 nicardipine Drugs 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000001177 vas deferen Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AKPNZOHONDXXES-UHFFFAOYSA-N 1-phenyl-2-propoxypiperazine Chemical compound CCCOC1CNCCN1C1=CC=CC=C1 AKPNZOHONDXXES-UHFFFAOYSA-N 0.000 description 1
- OUQMXTJYCAJLGO-UHFFFAOYSA-N 4-methyl-1,3-thiazol-2-amine Chemical compound CC1=CSC(N)=N1 OUQMXTJYCAJLGO-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- IFJOCHBDHXGFAA-UHFFFAOYSA-N CC([CH2-])=O.OCC(O)CO Chemical compound CC([CH2-])=O.OCC(O)CO IFJOCHBDHXGFAA-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000002908 adrenolytic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005792 cardiovascular activity Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- BGGXRVPCJUKHTQ-AHCAJXDVSA-L carumonam sodium Chemical compound [Na+].[Na+].O=C1N(S([O-])(=O)=O)[C@H](COC(=O)N)[C@@H]1NC(=O)C(=N/OCC([O-])=O)\C1=CSC(N)=N1 BGGXRVPCJUKHTQ-AHCAJXDVSA-L 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 125000005484 neopentoxy group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000926 not very toxic Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Definitions
- New derivatives of 4-methyl-thiazole processes for their preparation and pharmaceutical compositions containing them.
- the subject of the present invention is new derivatives of 4-methyl-thiazole, more specifically amino derivatives of 4-methyl-5-thiazole, their methods of preparation and pharmaceutical compositions containing them.
- the compounds according to the invention are derivatives of 4-methyl thiazole corresponding to the general formula:
- R 1 and R 2 are chosen from a hydrogen atom, a halogen atom, a hydroxy group, a trifluoromethyl group, an alkyl group having from 1 to 4 carbon atoms, an alkoxy group having from 1 to 5 carbon atoms.
- the invention also includes within its scope all the possible optical isomers of the compounds of formula (I) as well as their mixtures.
- the invention also includes within its scope the salts of the above-mentioned compounds of formula (I).
- a halogen atom is preferably a chlorine or fluorine atom.
- the alkyl and alkoxy groups can be straight or branched chain groups.
- An alkyl group having from 1 to 4 carbon atoms is for example a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, or tert-butyl group, preferably methyl or ethyl.
- alkoxy group having from 1 to 5 carbon atoms is for example a methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiobutoxy, n-pentoxy, isopentoxy or neopentoxy group, preferably methoxy, ethoxy, propoxy or isopropoxy.
- the general process for the preparation of the compounds according to the invention, of formula (I), as defined above, in laguelle n is equal to 0 comprises the condensation reaction of 5-bromo-4-methyl-thiazole on the sodium salt d 'a (4-aryl piperazinyl-1) -2-ethanol of formula:
- R 1 and R 2 have the same meaning as indicated above.
- 5-bromo-4-methyl-thiazole is obtained by bromination of 2-amino-4-methyl-thiazole under conditions allowing the obtaining of 2-amino-5-bromo-4-methyl-thiazole;
- Amino-2-methyl-4 thiazole is a known product, the preparation process of which is described in the literature (Merck Index, 10th edition, n ° 454).
- R 1 and R 2 have the same meaning as indicated above.
- (4-methyl-5 thiazolyloxy) -3-1,2-epoxy propane is obtained by:
- Glycerol acetonide (or 2,2-dimethyl-1,3-dioxolane-4 methanol), sold by the company ALDRICH, is a known product whose preparation process is for example described in Beilstein 19, 65, Merck Index 10, 3236.
- the compounds of formula (I) according to the invention and their pharmaceutically acceptable salts have advantageous pharmacological properties which suggest a therapeutic application of these compounds in particular in the treatment of cardiovascular manifestations linked to hyperactivity of the sympathetic nervous system of type ⁇ -adrenergic.
- the invention also aims to cover new pharmaceutical compositions, characterized in that they contain, in combination with a pharmaceutically acceptable excipient, at least one compound of formula (I) or its non-toxic addition salt, as a principle active.
- the pharmaceutically acceptable salts of the compounds of formula (I) are obtained in a manner known per se, by bringing the products of formula (I) into contact with a suitable quantity of pharmaceutically acceptable acid such as for example a mineral acid such as hydrochloric acid or sulfuric acid, or an organic acid such as citric, tartaric or fumaric acid.
- a suitable quantity of pharmaceutically acceptable acid such as for example a mineral acid such as hydrochloric acid or sulfuric acid, or an organic acid such as citric, tartaric or fumaric acid.
- compositions according to the invention can generally be prepared by conventional methods and administered in an appropriate pharmaceutical form.
- the compounds can be administered, for example, orally in 1 to 3 doses per day, at a rate of 2 to 2 mg per dose depending on the compound, for example in the treatment of cardiovascular manifestations linked to hyperactivity of the sympathetic nervous system of ⁇ -adrenergic type.
- the invention aims to cover a process for the preparation of a pharmaceutical composition, characterized in that a pharmaceutically effective amount of at least one compound of formula (I) as defined above is incorporated, or a non-toxic addition salt of this compound, in a pharmaceutically acceptable excipient.
- the invention aims to cover a method for the treatment of cardiovascular manifestations linked to hyperactivity of the sympathetic nervous system of the oc-adrenergic type, characterized in that it comprises administration to a mammal comprising man and l animal, of a therapeutically effective amount of at least minus a compound of formula (I) as defined above, or of a pharmaceutically acceptable addition salt of this compound.
- Step 1 Synthesis of 2-amino-5-bromo-4-methyl-thiazole.
- reaction medium is then filtered and the hydrobromide is washed with dichloromethane, then with pentane.
- the hydrobromide is dissolved in 2000 ml of water, then basified by the addition of 850 ml of 10% aqueous sodium bicarbonate solution.
- Step 2 Synthesis of 4-methyl-5-bromo thiazole.
- the reaction medium is left under stirring at this temperature for 30 min.
- the hypophosphorous acid (50%, 197 ml) is then added slowly to the reaction medium at -10 ° C.
- the reaction medium supplemented with dichloromethane is centrifuged at 3000 rpm for 15 min. After decantation and evaporation under vacuum of the solvent, the (4-o-ethoxyphenyl-piperazinyl-1) -2 ethanol is removed by fractional distillation under reduced pressure. The distillation residue is purified by chromatography on a column of silica gel (AcOEt).
- the hydrochloride is prepared in anhydrous ethyl ether by addition of dry HCl gas, then recrystallized from a mixture of isopropanol and pentane.
- Step 1 Synthesis of (4-methyl-5 thiazolyloxy) -3-1,2-propanediol acetonide.
- 5-bromo-4-methyl thiazole can be obtained by following the experimental process described in steps 1 and 2 of Example 1.
- the reaction medium is stirred for 15 h.
- the hydrochloride is crystallized from a mixture of isopropanol and ethyl ether.
- the base is released by adding a 10% sodium bicarbonate solution, then purified by recrystallization from a mixture of ethyl acetate and pentane (80/20). 19.1 g of white crystals are obtained.
- the reaction medium is heated for 10 h at 70 C.
- the filtrate is concentrated to dryness under reduced pressure and the (methyl -4 thiazolyloxy-5) -3 epoxy-1,2 propane is purified by chromatography on a column of silica gel (AcOEt). 6.75 g of epoxide are obtained, in the form of a pale yellow oil.
- Step 4 Synthesis of (4-o-propoxyphenyl-1 piperazinyl-1) -3 (4-methylthiazolyloxy-5) -1-propanol-2 monohydrochloride (B 1395).
- the reaction medium is heated at 40 ° C for 21 h.
- the solvent is removed by distillation under reduced pressure.
- the monohydrochloride is obtained by adding a stoichiometric amount of an ethanolic solution of hydrochloric acid previously dosed, in an ethanolic solution of the base cooled by an ice bath. After 1 h of stirring and elimination of the ethanol by distillation under reduced pressure, the product is crystallized from a mixture of ethyl ether and acetone and then recrystallized from acetone.
- mice I. Acute toxicity in mice.
- the products were administered orally at a single dose in male mice weighing 22 g. Mortality was recorded after a 14-day observation period.
- LD 50 lethal dose 50
- the concentration of product is determined in the presence of which the concentration of noradrenaline must be multiplied by two to obtain the same effect as in the absence of said product.
- the logarithm changed sign of this concentration constitutes the pA 2 of the products.
- noradrenaline 0.4 mg.kg -1
- the prior administration of a substance with an alpha-blocking property makes it possible to reduce this toxicity.
- B 1431, B 1510, B 1525, B 1548 and B 1552 prove to be particularly active in the whole animal, thus confirming their action demonstrated in vitro.
- Blood pressure is measured by catheterization of the left carotid artery in the anesthetized male rabbit.
- the increase in blood pressure is induced by an intravenous injection of norepinephrine. This hypertension can be inhibited by the prior administration of molecules with alpha-blocking potential.
- ID 50 50% inhibitory dose
- ID 50 the dose of product which, administered by IV, inhibits by 50% the arterial hyperpressure.
- Compound B 1395 is particularly effective with an active dose of less than 1 mg.kg V. Determination of cardiovascular activity
- the products are administered intravenously in increasing doses. Three animals are tested per product. The dose causing a 25% drop in average blood pressure
- the products have dose-dependent hypotensive effects but have little or no effect on the heart rate (Table 7).
- the most hypotensive in terms of effective dose is B 1395 (DE 25 at 0.004 mg.kg -1 ).
- the ED 25 evaluated 5 min after injection make it possible to locate the hypotensive potential of the products B 1395, B 1396, B 1431 and B1552 at the level of Nicardipine.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9001979 | 1990-02-19 | ||
FR9001979A FR2658514B1 (fr) | 1990-02-19 | 1990-02-19 | Nouveaux derives du methyl-4 thiazole, leurs procedes de preparation et les compositions pharmaceutiques en contenant. |
PCT/FR1991/000118 WO1991012246A1 (fr) | 1990-02-19 | 1991-02-14 | Nouveaux derives du methyl-4 thiazole, leurs procedes de preparation et les compositions pharmaceutiques en contenant |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0594595A1 true EP0594595A1 (de) | 1994-05-04 |
Family
ID=9393877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91904815A Withdrawn EP0594595A1 (de) | 1990-02-19 | 1991-02-14 | Neue 4-methyl-thiazol-derivate, verfahren zur herstellung und diese verbindungen enthaltende arzneimittel |
Country Status (8)
Country | Link |
---|---|
US (1) | US5322846A (de) |
EP (1) | EP0594595A1 (de) |
JP (1) | JPH05503537A (de) |
CA (1) | CA2075998A1 (de) |
FR (1) | FR2658514B1 (de) |
IE (1) | IE910540A1 (de) |
PT (1) | PT96808A (de) |
WO (1) | WO1991012246A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE203012T1 (de) * | 1994-03-30 | 2001-07-15 | Zeria Pharm Co Ltd | 4-indol-1-yl-buttersäure derivate, deren herstellung und deren verwendung als inhibitoren für alpha1-adrenerge rezeptoren und testosteron 5alpha-reduktasen |
DE19728996A1 (de) | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE756127A (fr) * | 1969-09-12 | 1971-03-15 | Hoechst Ag | Ethers heterocycliques et leur preparation |
US3850946A (en) * | 1972-07-10 | 1974-11-26 | Syntex Inc | 3-thiazol-5'-oxy-aminopropanol cardiovascular agents |
FR2209557A1 (en) * | 1972-12-12 | 1974-07-05 | Roussel Uclaf | Piperazo alkyl thiazolyl ketones/ethers - adrenolytics and antihypertensives prepd. from a piperazine and a halo alkyl thiazole |
FR2637596B1 (fr) * | 1988-10-11 | 1992-09-04 | Irceba | Methyl-4 ((aryl-4 piperazinyl-1)-2 ethyl)-5 thiazole et ses derives, leur procede de preparation et les medicaments en contenant |
-
1990
- 1990-02-19 FR FR9001979A patent/FR2658514B1/fr not_active Expired - Lifetime
-
1991
- 1991-02-14 JP JP3505502A patent/JPH05503537A/ja active Pending
- 1991-02-14 WO PCT/FR1991/000118 patent/WO1991012246A1/fr not_active Application Discontinuation
- 1991-02-14 US US07/916,846 patent/US5322846A/en not_active Expired - Fee Related
- 1991-02-14 EP EP91904815A patent/EP0594595A1/de not_active Withdrawn
- 1991-02-14 CA CA002075998A patent/CA2075998A1/en not_active Abandoned
- 1991-02-15 IE IE054091A patent/IE910540A1/en unknown
- 1991-02-19 PT PT96808A patent/PT96808A/pt not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9112246A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2075998A1 (en) | 1991-08-20 |
IE910540A1 (en) | 1991-08-28 |
JPH05503537A (ja) | 1993-06-10 |
US5322846A (en) | 1994-06-21 |
FR2658514B1 (fr) | 1992-06-19 |
PT96808A (pt) | 1991-10-31 |
WO1991012246A1 (fr) | 1991-08-22 |
FR2658514A1 (fr) | 1991-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH639653A5 (fr) | Aminothiazoles et composition pharmaceutique les contenant. | |
EP0702010A1 (de) | Benzopyranverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutischen Zubereitungen | |
EP0022118A1 (de) | Sulfonyl-anilin-Derivate, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung | |
EP0021940B1 (de) | Aminoderivate von Benzothiazol, Verfahren zu ihrer Herstellung und ihre Anwendung in der Heilkunde | |
WO1993020046A1 (fr) | Derives d'indane-1,3-dione et d'indane-1,2,3-trione, leurs procedes de preparation et leur application en therapeutique | |
EP0364350B1 (de) | 4-Methyl-5[2-(4-phenyl-1-piperazinyl)-ethyl]-Thiazolderivate, ihre Herstellung und Zusammenstellungen, die sie enthalten | |
FR2558158A1 (fr) | Derives de l'indole ethenyl phenol, leurs sels, procede de preparation, application a titre de medicaments, compositions les renfermant et intermediaires | |
WO1991012246A1 (fr) | Nouveaux derives du methyl-4 thiazole, leurs procedes de preparation et les compositions pharmaceutiques en contenant | |
EP0063084A1 (de) | Phenethanolamin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
EP0209435B1 (de) | Hydroxyalkoxy-4-phenylpropylindolderivate, ihre Salze, Verfahren und Zwischenprodukte zur Herstellung, Anwendung als Heilmittel und Zusammensetzungen die sie enthalten | |
CA1100968A (fr) | Procedes de preparation de nouvelles piperazines disubstituees | |
EP0005091B1 (de) | Monosubstituierte Piperazine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate | |
EP0347305B1 (de) | [(Aryl-4-piperazinyl-1)-2-ethoxy]-3p-cymole, die ortho-, meta-, para-monosubstituierten oder disubstituierten Derivate, das Verfahren zu deren Herstellung und die als aktives Prinzip diese Verbindungen enthaltenden Arzneimittel | |
EP0275221B1 (de) | N-(1H-indol-4-yl)-Benzamidderivate, ihre Salze und deren Anwendung als Heilmittel und Zusammenstellungen, die sie enthalten | |
EP0323303B1 (de) | Nicotinoylpiperazin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie | |
CH634075A5 (en) | Process for the preparation of hydrated imidazothiazole and thiazolopyrimidine derivatives having an anti-inflammatory activity | |
FR2692894A1 (fr) | Aryl-1-(o-alcoxy-phényl-4-pipérazinyl-1)-2, 3- ou 4-alcanols, leur procédé de préparation et leur utilisation pour la préparation de médicaments. | |
EP0092450A1 (de) | Tryptaminderivate mit Wirkung auf das Kardiovaskuläre System und Verfahren zu ihrer Herstellung | |
FR2539127A1 (fr) | Nouveaux derives du 4h-1,2,4-triazole, leur procede de preparation et leur application comme medicaments | |
FR2508032A1 (fr) | Nouveaux derives amino-3 aryloxymethyl-2 propanol-1, leur procede de preparation et leurs applications en therapeutique | |
CA1068270A (fr) | Diamino-2,4-bromo-5 chloro-6 pyrimidines utilisables comme medicaments et procede pour leur preparation | |
FR2481278A1 (fr) | Nouveaux derives de piperidine, leur procede de preparation et leur application en therapeutique | |
EP0237411A1 (de) | (Piperidin-3)-propoxy-5p-cymol, seine Acetyl-, Acetoxy- und Hydroxy-Derivate, Salze dieser Produkte, Verfahren zur Herstellung dieser Verbindungen und mindestens eines dieser Produkte als aktives Prinzip enthaltende Arzneimittel | |
EP0070779A2 (de) | Bisortho substituierte Phenole, von denen eine der Substituenten ein Heterozyklus ist, Verfahren zu deren Herstellung, deren anti-hypertensieve pharmazeutische Zusammensetzungen und Herstellungs-Zwischenprodukte | |
BE878563A (fr) | Nouvelles alpha-alkyl-o-oxybenzylamines, leur preparation et leur application comme medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19920707 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19960903 |